Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
"And don’t fall for his comment about keeping 90% and only trading 10%. It’s total nonsense and doesn’t make sense. He will sell all of it when he thinks the time is right. And I promise you he will let you know with his subtle negative posts."
What's your rationale for thinking that only trading 10% doesn't make sense?
I firmly believe that no one can consistently time the market hence why I don't myself try and trade any amount. However, if I wanted to try giving it a go then keeping a core holding of say 90% and trading 10% on the margins seems like a perfectly reasonable strategy. Some of those 10% trades might pay off but if they don't you wouldn't be too badly burnt as you still have your core 90% long.
As for Sangi's supposed occasional deramping, on the basis of their posts that I've read over the last few months I disagree. There's a difference between being negative and being objective. I don't always agree with their opinion but there's nothing wrong with that. As far as I'm concerned they come across as objective rather than negative and certainly a lot more objective than some who post on here, which is a good thing.
Don't remember seeing any negative posts from Sangi.
And also what have I said that was rampy? I just agreed with others that the financing was good news.
Get a grip
Have you got an example of one of these subtle negative posts. You really need to back up your libel with facts
Just because I am not a mindless ramper like many on here.
I have been in since 2018 and will probably still be in in 2025. That's why I know more about the company than so many here.
A trader would not have done so much research.
And don’t fall for his comment about keeping 90% and only trading 10%. It’s total nonsense and doesn’t make sense. He will sell all of it when he thinks the time is right. And I promise you he will let you know with his subtle negative posts.
Stay Long
Show me 1 post where I have been negative on 4D
I have challenged moronic trader rampers
Those claiming that solely by listing on Nas there would be a rapid rerate to £5 a share
And I recently was critised for talking the share down because I said the 0518 data was not due at the end of June but maybe in Autumn
The one thing that is for sure it that as soon as Sang1 has sold he will slip bank into de ramp mode. Although it appears that he is very knowledgeable about 4d from my experience it’s best not to take him too seriously. He’s a trader and will try and influence investors either to buy or sell, whichever suits him at the time. At the moment he is in positive mode and has probably changed his view on his see price. Probably see him sell late 90’s now
He hasn't sold anything yet, order's sitting at 92. I reckon it'll probably get hit before US open. Not sure if he then can buy back sub-90 though. I doubt it big time.
So the additional cash may mean a rapid move into Phase 1B of the asthma trial explaining the additional sites in the US and Bradford or maybe the P3 Blautix trial in house rather than out-licensing?
Obviously not talking about selling entire holding at 92, just the 10% or so that I trade on the dips and spikes
Looks to me like most of those sellers are retail and taking their losses. We've seen many spikes and subsequent pullbacks recently so they're assuming this is another of them. Boy I'd love to see them get this wrong and a whopping 108 close (instead of 88).
You haven't been here long Biker, have you?
The rule is sell on news then buy the fall back, which I haven't done today as I was hoping for 92
It would be commercially sensitive because any debt creates a liability on the balance sheet. As the money is drawn down the "value" of the company declines....
Not necessarily material but important hence the sensitivity.
Because when other companies approach Oxford for bespoke finance they could use 4D as the reference rate for their loan e. g. push for a lower rate on the basis of the info.
As you will see from info published on other deals there's no talk of the rate
https://www.businesswire.com/news/home/20210512005662/en/Oxford-Finance-Provides-125-Million-Credit-Facility-to-Kala-Pharmaceuticals
I also invest in an Aim company called Ideagen who can actually borrow from the likes of Santander. They don't tell you the interest rate either, the financial statement will just have an entry for the amount spent on debt.
Hi Sang and StayLong, I am sure due diligence was done, and it looks like they have confidence in the company to make an interest only loan. The payments will have to be laid out in the next company financial statement so I don't know why this would be considered commercially sensitive. Am I missing something?
In the meantime, I am looking forward to more trials and - hopefully - great results.
One thing for sure is that the due diligence would have been very thorough and they must of liked what they saw
Now that most of the day traders seem to have disappeared from this share I can foresee a steady climb up to a more sensible SP.
Zaphod the interest rate would not be disclosed as it's commercially sensitive for the lender and 4D with regard to any future deals they each might negotiate
This seems a vote of long term confidence from an experienced American finance house, and underpins trial funding at least for the next year. I would like to see more detail however to be able to judge this deal ie what is the cost of the financing. I see no mention of the interest rate to be charged, which I would have thought was a fairly important variable for investors to know in order to judge how good this deal is.
About Oxford Finance LLC
Oxford Finance is a specialty finance firm providing senior secured loans to public and private life sciences and healthcare services companies worldwide. For over 20 years, Oxford has delivered flexible financing solutions to its clients, enabling these companies to maximize their equity by leveraging their assets. In recent years, Oxford has originated over $7 billion in loans, with lines of credit ranging from $5 million to $150 million. Oxford is headquartered in Alexandria, Va., with additional offices in San Diego, Calif.; Palo Alto, Calif.; and the greater Boston and New York City areas. For more information, visit
https://oxfordfinance.com/
Nice job on this finance. Oxford finance clearly believe DDDD will deliver.
I think it’s fantastic news. Basically this lender has lent money with no security. This is another serious vote of confidence. 4d has more potential than any other share on AIM. Not only potential but a no brainer at that ridiculous SP.
Seems like great news to me - extends cash runway into Q4 2022, with multiple trial readouts due before then, and gives 4D more time to find a new CFO. Hopefully that settles any concerns about a further share placing, and the share price can finally start re-rating.
Giving away $250k of shares in return for a $12.5m loan isn't a bad deal either; I've seen far worse on AIM.